Third quarter 2020 financial report

29. Oct 2020 | 2 min read

Moss, 29 October 2020

Gentian Diagnostics AS announces its results for the third quarter of 2020. The highlights include:

  • Sales revenue for the first nine months of MNOK 46.1 representing 36 % growth (24 % adjusted for currency effects) compared to the same period last year
  • Gentian’s Swedish distribution subsidiary, Gentian Diagnostics AB, has had a sales growth from third party products of 52 % YTD 2020 compared to the same period last year
  • Scientific Advisory Board for NT-proBNP (formerly called G-1001) Established
  • Study confirms significantly elevated levels of calprotectin in patients with severe COVID-19, which is an opportunity for our GCAL® assay

Please find the report and results presentation here:

GDAS Interim Report 3Q 2020
GDAS Interim Presentation 3Q 2020


For further information, please contact:

Hilja Ibert CEO, Gentian Diagnostics
Cell Phone: +47 919 05 242

Njaal Kind CFO, Gentian Diagnostics
Cell Phone. +47 919 06 525

MeldingsID: 516640
UtstederID: GENT-ME
Marked: Merkur Market

You may also read

Feb 11, 2021 - Kristin Hart

4Q 2020 Results and preliminary annual report

Moss, 11 February 2020 Gentian Diagnostics AS announces its results for the 4th quarter and 2020 preliminary..

Jan 22, 2021 - Kristin Hart

SARS-CoV-2 antibody test moving to the next development phase

Moss, 22.01.2021 Gentian Diagnostics AS is pleased to announce that its high-throughput SARS-CoV-2 antibody..